Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Sensei Biotherapeutics Inc (SNSE)

$21.00 +0.27 (1.30%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	27.80M
Revenue (ttm)	0.00
Net Income (ttm)	-21.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	28,400
Avg Vol	66,758
Day's Range	N/A - N/A
Shares Out	1.34M
Stochastic %K	2%
Beta	-0.18
Analysts	Sell
Price Target	$50.00

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

petersadick May. 11 at 8:35 PM

$SNSE great job management, at this rate we will be at zero value in less than 10 days

0 · Reply

SuperGreenToday May. 6 at 9:34 PM

$SNSE

0 · Reply

DARKP00L May. 5 at 11:35 AM

$SNSE 07:34 on May. 05 2026 Sensei Biotherapeutics Says First Patient Dosed In Study FTH-PIK-101, Phase 1b/2 Trial Of PIKTOR In Patients With HR+/HER2- Advanced Breast Cancer #tradeideas

1 · Reply

InvestingSpaceman May. 4 at 9:47 PM

$SNSE $MMTLP $NWBO $XYN $CYN ANA

0 · Reply

Murphynl87 Apr. 28 at 5:41 PM

$SNSE I go out at 35.

0 · Reply

DARKP00L Apr. 28 at 11:32 AM

$SNSE 07:29 on Apr. 28 2026 Sensei Biotherapeutics Files Prospectus To Register 24.9M Shares For Resale By Selling Shareholders #tradeideas

0 · Reply

InvestingSpaceman Apr. 27 at 10:52 PM

$AZI $WBUY $BYND $SNSE 40+

0 · Reply

ManiaTrader Apr. 22 at 11:21 PM

$SNSE Any interest here at all or huge news and they will not be able to control the price action me thinks.

0 · Reply

ManiaTrader Apr. 22 at 11:12 PM

$SNSE Short interest at 106%. Float is tiny!!! I bought 1,000 shares after hours at $32. Worth the risk for me.

0 · Reply

ManiaTrader Apr. 21 at 9:57 PM

$SNSE Over 100% float is short. Good cash and good line. May be worth a few bucks.

0 · Reply

Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial

May 5, 2026, 7:30 AM EDT - 8 days ago

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

2026-04-28T12:14:12.000Z - 15 days ago

Sensei Biotherapeutics files to sell 24.87M shares of common stock for holders

Apr 16, 2026, 12:45 PM EDT - 26 days ago

Sensei Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:30 AM EDT - 4 weeks ago

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-30T11:36:33.000Z - 6 weeks ago

Sensei Biotherapeutics reports FY25 EPS ($16.72) vs ($24.01) last year

Mar 30, 2026, 7:30 AM EDT - 6 weeks ago

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

2026-03-17T10:16:33.000Z - 2 months ago

Sensei Biotherapeutics announces inducement grants under Nasdaq listing rule

Mar 17, 2026, 6:00 AM EDT - 2 months ago

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-02-20T14:56:02.000Z - 2 months ago

Sensei Biotherapeutics Inc trading resumes

2026-02-20T14:50:42.000Z - 2 months ago

Sensei Biotherapeutics Inc trading halted, volatility trading pause

2026-02-18T14:45:38.000Z - 2 months ago

Sensei Biotherapeutics Inc trading resumes

2026-02-18T14:41:02.000Z - 2 months ago

Sensei Biotherapeutics Inc trading halted, volatility trading pause

2026-02-18T13:36:23.000Z - 2 months ago

Sensei Biotherapeutics acquires Faeth Therapeutics

Feb 18, 2026, 8:30 AM EST - 2 months ago

Sensei Biotherapeutics Transcript: M&A announcement

Feb 18, 2026, 8:00 AM EST - 2 months ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Jan 7, 2026, 8:00 AM EST - 4 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

2025-11-14T12:35:31.000Z - 6 months ago

Sensei Biotherapeutics reports Q3 EPS ($3.62) vs ($5.77) last year

Nov 14, 2025, 7:30 AM EST - 6 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

2025-10-30T15:05:43.000Z - 6 months ago

H.C. Wainwright downgrades Sensei on shelving of solnerstotug

2025-10-30T15:00:39.000Z - 6 months ago

Sensei Biotherapeutics downgraded to Neutral from Buy at H.C. Wainwright

2025-10-30T13:55:14.000Z - 6 months ago

Sensei Biotherapeutics Inc trading resumes

2025-10-30T13:06:56.000Z - 6 months ago

Sensei initiates strategic review, implements workforce reduction

Oct 30, 2025, 9:00 AM EDT - 6 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

2025-10-30T12:55:14.000Z - 6 months ago

Sensei Biotherapeutics Inc trading halted, news pending

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Sensei Biotherapeutics Transcript: KOL Event

2025-10-17T13:55:40.000Z - 7 months ago

Sensei Biotherapeutics Inc trading resumes

2025-10-17T13:50:26.000Z - 7 months ago

Sensei Biotherapeutics Inc trading halted, volatility trading pause

2025-10-17T12:16:15.000Z - 7 months ago

Sensei Biotherapeutics reports results from Phase 1/2 trial of solnerstotug

Oct 17, 2025, 8:00 AM EDT - 7 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

2025-10-16T18:20:13.000Z - 7 months ago

Sensei Biotherapeutics Inc trading resumes

Sep 23, 2025, 7:30 AM EDT - 8 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Sensei Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 5:30 PM EDT - 1 year ago

Sensei Biotherapeutics Transcript: Study Update

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 11, 2025, 10:40 AM EST - 1 year ago

Sensei Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 18, 2024, 2:30 PM EDT - 1 year ago

Sensei Biotherapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Sensei Biotherapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Sensei Biotherapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Sensei Biotherapeutics Transcript: Study Update

May 30, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 2 years ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Feb 14, 2024, 10:00 AM EST - 2 years ago

Sensei Biotherapeutics Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

petersadick May. 11 at 8:35 PM

$SNSE great job management, at this rate we will be at zero value in less than 10 days

0 · Reply

SuperGreenToday May. 6 at 9:34 PM

$SNSE

0 · Reply

DARKP00L May. 5 at 11:35 AM

$SNSE 07:34 on May. 05 2026 Sensei Biotherapeutics Says First Patient Dosed In Study FTH-PIK-101, Phase 1b/2 Trial Of PIKTOR In Patients With HR+/HER2- Advanced Breast Cancer #tradeideas

1 · Reply

InvestingSpaceman May. 4 at 9:47 PM

$SNSE $MMTLP $NWBO $XYN $CYN ANA

0 · Reply

Murphynl87 Apr. 28 at 5:41 PM

$SNSE I go out at 35.

0 · Reply

DARKP00L Apr. 28 at 11:32 AM

$SNSE 07:29 on Apr. 28 2026 Sensei Biotherapeutics Files Prospectus To Register 24.9M Shares For Resale By Selling Shareholders #tradeideas

0 · Reply

InvestingSpaceman Apr. 27 at 10:52 PM

$AZI $WBUY $BYND $SNSE 40+

0 · Reply

ManiaTrader Apr. 22 at 11:21 PM

$SNSE Any interest here at all or huge news and they will not be able to control the price action me thinks.

0 · Reply

ManiaTrader Apr. 22 at 11:12 PM

$SNSE Short interest at 106%. Float is tiny!!! I bought 1,000 shares after hours at $32. Worth the risk for me.

0 · Reply

ManiaTrader Apr. 21 at 9:57 PM

$SNSE Over 100% float is short. Good cash and good line. May be worth a few bucks.

0 · Reply

stockanalysis_ Apr. 19 at 12:24 AM

$AREB $SNSE $CAR $NGNE $AZI

0 · Reply

SqueezeSharkie Apr. 17 at 4:54 PM

$SNSE Was in this one super early, make sure to follow and put your notifications on!!

0 · Reply

TheDipMaster Apr. 17 at 5:23 AM

$SNSE how is this possible?

1 · Reply

Murphynl87 Apr. 16 at 3:46 PM

$SNSE Any expectations about the conference?

0 · Reply

AtlasAnalysis Apr. 16 at 1:11 PM

$SNSE has another move left just needs volume

0 · Reply

ThisStockisDogShit Apr. 14 at 4:44 PM

$CAR $HTZ $SNSE With just a very small proportion of your gains. Join me in sending SNSE to 300+ 👀🤷‍♂️ 106% short interest. Daily volume 5.6k. This is the everything squeeze.

0 · Reply

MetricWhale Apr. 14 at 1:44 PM

$SNSE absolutel banger! Dont worry if you missed it there's more to come.

0 · Reply

HustlerTV Apr. 13 at 7:26 PM

$SNSE interesting and lots of chit chat here MBAI swinging this into the merger 5+ coming

0 · Reply

JackBullskin Apr. 12 at 12:42 AM

$BFRG $SNSE Yes that was predictable

0 · Reply

JackBullskin Apr. 12 at 12:42 AM

$BFRG $SNSE

0 · Reply

1.0.0